Vivian Ng

1.3k total citations · 1 hit paper
10 papers, 955 citations indexed

About

Vivian Ng is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Vivian Ng has authored 10 papers receiving a total of 955 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 5 papers in Pulmonary and Respiratory Medicine and 4 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Vivian Ng's work include HER2/EGFR in Cancer Research (6 papers), Monoclonal and Polyclonal Antibodies Research (3 papers) and Gastric Cancer Management and Outcomes (3 papers). Vivian Ng is often cited by papers focused on HER2/EGFR in Cancer Research (6 papers), Monoclonal and Polyclonal Antibodies Research (3 papers) and Gastric Cancer Management and Outcomes (3 papers). Vivian Ng collaborates with scholars based in United States, Italy and Belgium. Vivian Ng's co-authors include Michaela Lehle, Ellie Guardino, Edith A. Perez, Sara A. Hurvitz, Barbara Tong, Oliver Stoß, Luc Dirix, J. Vinholes, Yu-Waye Chu and Marlène Thomas and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Breast Cancer Research.

In The Last Decade

Vivian Ng

9 papers receiving 936 citations

Hit Papers

HER2 screening data from ToGA: targeting HER2 in gastric ... 2014 2026 2018 2022 2014 100 200 300 400

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Vivian Ng United States 7 709 404 376 205 99 10 955
Takahiro Kamio Japan 9 775 1.1× 600 1.5× 313 0.8× 169 0.8× 188 1.9× 20 1.1k
Jasmeet Singh United States 16 867 1.2× 501 1.2× 306 0.8× 164 0.8× 96 1.0× 40 1.1k
J. Goeminne Belgium 4 484 0.7× 384 1.0× 297 0.8× 135 0.7× 69 0.7× 7 867
S-A. Im South Korea 18 799 1.1× 454 1.1× 163 0.4× 324 1.6× 87 0.9× 85 1.1k
Feng-yi Feng China 8 450 0.6× 345 0.9× 109 0.3× 177 0.9× 129 1.3× 35 673
Kaku Saito Japan 13 1.3k 1.8× 913 2.3× 470 1.3× 303 1.5× 324 3.3× 36 1.7k
Naoki Takegawa Japan 13 533 0.8× 308 0.8× 256 0.7× 151 0.7× 156 1.6× 28 732
Aikseng Ooi Japan 10 276 0.4× 210 0.5× 117 0.3× 327 1.6× 161 1.6× 18 654
Marta Bonotto Italy 18 695 1.0× 443 1.1× 87 0.2× 233 1.1× 60 0.6× 52 1.0k
Helena Melezínková United States 7 623 0.9× 624 1.5× 60 0.2× 192 0.9× 266 2.7× 9 1.0k

Countries citing papers authored by Vivian Ng

Since Specialization
Citations

This map shows the geographic impact of Vivian Ng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vivian Ng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vivian Ng more than expected).

Fields of papers citing papers by Vivian Ng

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vivian Ng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vivian Ng. The network helps show where Vivian Ng may publish in the future.

Co-authorship network of co-authors of Vivian Ng

This figure shows the co-authorship network connecting the top 25 collaborators of Vivian Ng. A scholar is included among the top collaborators of Vivian Ng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vivian Ng. Vivian Ng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
Schöffski, Patrick, Sara Cresta, Ingrid A. Mayer, et al.. (2018). A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer. Breast Cancer Research. 20(1). 109–109. 67 indexed citations
2.
Xie, Xuanqian, et al.. (2018). Calibrating Time-Dependent One-Year Relative Survival Ratio for Selected Cancers. Lobachevskii Journal of Mathematics. 39(5). 722–729.
4.
Saura, Cristina, Evandro de Azambuja, Mafalda Oliveira, et al.. (2016). LORELEI: A Phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib (GDC-0032) versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative, early-stage breast cancer.. Journal of Clinical Oncology. 34(15_suppl). TPS613–TPS613. 4 indexed citations
5.
Cutsem, Eric Van, Yung‐Jue Bang, Feng-yi Feng, et al.. (2014). HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer. 18(3). 476–484. 426 indexed citations breakdown →
6.
Cosson, Valérie, Vivian Ng, Michaela Lehle, & Bert L. Lum. (2014). Population pharmacokinetics and exposure–response analyses of trastuzumab in patients with advanced gastric or gastroesophageal junction cancer. Cancer Chemotherapy and Pharmacology. 73(4). 737–747. 87 indexed citations
8.
Hurvitz, Sara A., Luc Dirix, Judit Kocsis, et al.. (2013). Phase II Randomized Study of Trastuzumab Emtansine Versus Trastuzumab Plus Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer. Journal of Clinical Oncology. 31(9). 1157–1163. 302 indexed citations
10.
Ng, Vivian, et al.. (1996). CT evaluation of treatment response in advanced gastric cancer. Clinical Radiology. 51(3). 214–220. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026